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PRICE DISCRIMINATION IN
THE UNITED STATES: WHY ARE
PHARMACEUTICALS CHEAPER IN





A group of elderly citizens climbs onto a bus that was sent by their
U.S. senator. At first glance, it appears to be another political
candidate's effort to ensure that these senior citizens make it to
the polling booths. But as the bus crosses the U.S.-Canadian border, one
realizes that these riders aren't headed to their precinct polling locations.
Instead, they are traveling to Canada to purchase prescription drugs!
When politicians focus campaign attention on the high cost of prescrip-
tion drugs, they tend to aim their message at senior citizens because that
group constitutes forty two percent of the prescription drug market.'
Vermont Senator Bernard Sanders, inspired some of his political col-
leagues to organize bus trips to take senior citizens to Canada to purchase
prescription medicines, in an effort to politicize, once again, the issue of
rising prescription drug costs. 2 Recently, Senator Debbie Stabenow of
Michigan organized such a trip. Hundreds of senior citizens from across
the nation climbed aboard to ride the Rx Express from Detroit to Wind-
sor, Canada to purchase medicines.3 Senator Tim Johnson of South Da-
kota also scheduled a bus trip for senior citizens in August of 2002 to visit
* Juris Doctorate candidate at SMU, graduating in December 2003. Bachelor of
Science in Biology from University of North Texas in 1997. Masters in Business
Administration from University of North Texas in 2000.
1. News Release, AARP, AARP Enters Three Federal Lawsuits to Bring Lower-
Priced Drugs to Consumers (May 29, 2002), available at http://www.aarp.orglpress/
2002/nr052902drugs.html.
2. See Curtis Koren, How Far Would You Go for Cheaper Drugs?, Lycos Health with
WebMD (July 14, 2000), at http://webmd.lycos.com/content/articlel1691-50450.
3. Press Release, Senator Debbie Stabenow, U.S. Senator Debbie Stabenow and the
Alliance for Retired Americans Kick off Rx Express Bus Trip to Canada (June 10,
2002), at http://stabenow.senate.gov/press/2002/061002rxexpress.htm.
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a doctor in Winnipeg, Canada and to have their prescriptions filled.4
Although many of these bus trips have been criticized as mere cam-
paign ploys in election years, senior citizens do not seem to mind. Many
senior citizens living on fixed incomes welcome the opportunity to go to
Canada to fill prescriptions because it saves them money.5 Jane Hanlon,
a 71-year-old hairdresser living in Vermont, was paying $95 a month at a
local pharmacy to purchase Tamoxifen which she takes for her breast can-
cer-now she gets it in Canada for $10.42 a month.6 Seventy-four year
old Viola Quirion of Waterville, Maine takes a bus trip to Canada every
three months to purchase Prilosec to aid with stomach troubles and
Relofen for arthritis.7 Other popular drugs are available at big savings as
well: a three-month supply (180 pills) of Tamoxifen, a cancer-fighting
drug, costs $298 in the United States, but only $26 in Canada;8 forty-five
capsules of Prozac retails for $115 in the United States, but only $35 in
Canada. 9 During one trip in August 2002, a group of seniors saved, in
aggregate, more than $18,000 on prescriptions, according to Chellie Pin-
gree, a U.S. Senate candidate from Maine. 10 Pingree took several trips to
Canada in 2002 with Maine seniors to raise awareness of the longstanding
problem of high drug costs in the United States." High prescription drug
cost is an important issue that receives heightened attention during an
election year, since an estimated sixty-five million Americans do not have
prescription drug coverage.12 This number includes both uninsured indi-
viduals and senior citizens who are Medicare beneficiaries, but not en-
rolled in any prescription drug program. 13 An estimated 30 percent of all
Medicare enrollees do not have drug coverage,' 4 which makes the high
cost of drugs of particular importance to many senior citizens. As a re-
sult, politicians focus on the issue in election years.
4. Scott Waltman, Johnson Schedules Another Bus Trip, Democratic Senatorial Cam-
paign Committee (Aug. 21, 2002), at http://www.dscc.org/newsroom/
inthenews082302.
5. See, e.g., Health Care: U.S. Seniors Travel to Canada by the Busloads for Deals.





8. Robert Lenzner, The Effects Could Be Devastating, FORBES (Nov. 27, 2000), 2000
WL 25964120.
9. Id.
10. Jennifer John, Head North for Prescriptions, SOLIDARITY (Oct. 2002), at http://
www.uaw.org/solidarity/02/1002/featuresO5.html.
11. Id.
12. Familes USA, Profiting from Pain: Where Prescription Drug Dollars Go, FAMILIES
USA FOUNDATION (July 2002), at 14, at http://www.familiesusa.org [hereinafter
Profiting from Pain].
13. Steven Findlay, Prescription Drug Expenditures in 2000: The Upward Trend Con-
tinues, I HEALTH CARE Focus 1, 1-3 (June 2001), at http://www.healthnet.com/
brokers/pdf/A9851 FOCUSJune.pdf.
14. Profiting from Pain, supra note 12, at 15.
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II. WHY ARE DRUGS APPRECIATIVELY MORE EXPENSIVE
IN THE UNITED STATES THAN ELSEWHERE?
While it is generally accepted that prescription drugs cost too much in
the United States, experts disagree on the reasons. As indicated above,
drug prices are higher in the United States than for its neighbors to the
north and south, and expenditures on prescription drugs are on the rise.15
Experts blame the high cost of prescription drugs on an array of factors:
capital expenditures on research and development (R&D); the industry's
quest for maximizing shareholder profits; heavy spending on advertising
and marketing; high compensation for drug company executives; recap-
turing profits lost to compulsory discounts given to federal purchasers;
and recapturing profits lost when drug companies are forced to charge
lower prices in countries that heavily regulate the pharmaceutical indus-
try, such as Canada. 16
A. COSTS OF RESEARCH AND DEVELOPMENT
One reason cited for the high price of prescription drugs is that the
pharmaceutical industry spends enormous capital on R&D. Brand-name
pharmaceutical manufacturers spent more than $30 billion on research in
2001.17 Developing a single drug costs in excess of $800 million and takes
an average of eleven years from creation to market. 18
Although the pharmaceutical industry claims that its high expenditures
on R&D are essential to discovering innovative and more effective drugs,
independent studies show that the industry has not introduced many new
and innovative drugs to the market in the last decade. 19 According to
National Institute for Health Care Management Research and Education
Foundation, 65 percent of new drugs approved by the FDA from 1989 to
2000 contained active ingredients already present in products available on
the market. 20 In fact, drug manufacturers are only marginally improving
existing drugs and then selling them at a higher price.
R&D is clearly integral to discovering and manufacturing innovative
drugs; however, drug companies, on average, allocate only 11 percent of
total revenue to R&D. 21 This number is seemingly inconsistent with the
15. See Findlay, supra note 13, at 3 (indicating that increases in spending for prescrip-
tion drugs will be between 12 and 23% per year through 2004).
16. See generally, Profiting from Pain, supra note 12 (article explores in detail the rea-
sons attributed to the high cost of drugs in America).
17. Joe Moser, Link between Drug Company Profitability and Investments in Research:
A Fact Sheet (July 2, 2002), at http://www.galen.org/news/070202.html. This is a
summary of a Tufts Center study.
18. Id.
19. Robert Dodge, As Costs Soar, So Does Desire For Latest Drugs (May 27, 2002), at
http://www.lef.org/newsarchive/aging/2002/05/27/krtbn/0000-0126-DA-PHARM.
html.
20. Michie Hunt, Changing Patterns of Pharmaceutical Innovation, NAT'L. INST. FOR
HEALTH CARE MGMT. RESEARCH & EDUC. FOUND. 3 (May 2002), at http://www.
nihcm.org/innovations.pdf.
21. Profiting from Pain, supra note 12, at 10.
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pharmaceutical industry's claim that the main cause for the high cost of
prescription drugs is the amount of capital spent on R&D. Furthermore,
the industry's explanation that drug costs are a reflection of high R&D
expenditures is not convincing given that 40 percent of most pharmaceu-
tical companies' R&D budgets are paid by the National Institute of
Health, whose budget is funded by U.S. taxpayers. 22
B. PROFITABILITY OF PHARMACEUTICAL COMPANIES
The pharmaceutical industry has been the most profitable industry in
the United States for each of the last ten years, according to a report by
Families USA. 23 On average, the pharmaceutical industry's profits have
been one-and-one-half times that of the next most profitable industry.24
The industry has been successful in continually maximizing shareholders'
wealth. In the last five years, shareholders of pharmaceutical stocks have
enjoyed an annual rate of return of 18.4 percent-twice the 9.2 percent
average return to stockholders of the Fortune 500 companies. 25 The
pharmaceutical industry leaders' position is that high drug prices are cen-
tral to maintaining high levels of profitability, which are essential to at-
tract new capital, which is necessary for R&D.26
Proponents of the U.S. pharmaceutical industry point out that although
the companies' profit margins are high, brand-name drug manufacturers
pay more taxes than most other companies. 27 However, according to a
1999 report from the Congressional Research Service, the pharmaceutical
industry's average tax rate of 16.2 percent is less than other industries,
which average a tax rate of 23.7 percent. 28 The report also showed that in
1996, the pharmaceutical industry reduced its tax bill by almost $3.8 bil-
lion,29 by taking advantage of tax credits related to research invest-
ments.30 Therefore, drug companies actually benefit from spending
revenues on R&D since such spending allows the industry to avoid pay-
ing higher taxes and increasing net profits.
C. SPENDING ON MARKETING, ADVERTISING, AND ADMINISTRATION
As new drugs emerge, drug companies spend significant budgets on
television and print ads targeting the general public. On average, phar-
maceutical manufacturers spend 27 percent of their revenues on market-
ing, advertising, and administration. 31 Also, on average, the top nine
22. Lenzner, supra note 8, at 3.
23. Profiting from Pain, supra note 12, at 13.
24. Id.
25. Id.
26. Id. at 14.
27. Moser, supra note 17, at 1.
28. Pharmaceutical Companies Pay Lowest Tax Rate of Any Industry, Soc. SEC. &
MEDICARE ADVISOR (Apr. 2000); available at http://www.tscl.org/NewContent/
100048.asp [hereinafter Pharmaceutical Companies].
29. Id.
30. See id.; Profiting from Pail, supra note 12, at 10.
31. Profiting from Pain, supra note 12, at 5.
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brand-name drug manufacturers have a much higher number of employ-
ees committed to non-research activities: they employ 81 percent more
people in marketing departments than in R&D. 32 Between 1995 and
2000, research personnel in these nine companies declined by 2 percent,
while marketing staff increased by 59 percent. 33 For example, Merck, the
manufacturer of popular drugs such as Vioxx, Singular, and Zocor, had 85
percent of its 78,100 employees engaged in non-research activities in
2001.34
D. EXECUTIVE COMPENSATION
Chief Executive Officers and other executive positions in the pharma-
ceutical industry are often paid much more than are those in commensu-
rate positions in other industries. In 2001, the average annual income of
the highest-paid executive in nine of the major brand-name pharmaceuti-
cal manufacturers was just shy of $21 million.35 That figure does not in-
clude unexercised stock options, which averaged $48 million in 2001.36 In
2001, the highest paid executive in the industry was Bristol-Myers
Squibb's former Chairman and CEO, C.A. Heimbold, Jr., whose compen-
sation exclusive of unexercised stock options was $74,890,918. 37
E. RECOUPING PROFITS LOST TO DISCOUNTS GRANTED TO
"MOST FAVORED PURCHASERS"
Pharmaceutical manufacturers are required by law to give the four
largest federal customers a 24 percent discount.38 In the private sector,
pharmacy benefit managers (PBMs) of large insurance companies and
health maintenance organizations (HMOs) negotiate with drug manufac-
turers for discounts, in return for granting the drugs preferred formulary
status.39 In accordance with the Omnibus Budge Reconciliation Act of
1990 (OBRA), manufacturers must give discounts to Medicaid. 40 Since
pharmaceutical manufacturers are forced to sell at a cheaper price to
these "most favored purchasers," costs are shifted to uninsured cash pay-
ing retail customers, many of whom are elderly.41 In 1999, a report was
prepared for the House Committee on Government Reform comparing
32. Id. at 13.
33. Alan Sanger & Deborah Socolar, Drug Industry Marketing Staff Soars While Re-
search Staffing Stagnates, BOSTON U. SCH. OF PuB. HEALTH REFORM PROGRAM
(Dec. 6, 2001), available at http://rxpolicy.com/studies/bu-rxpromotion-v-randd.
pdf.
34. Profiting from Pain, supra note 12, at 12.
35. Id. at 5.
36. Id. at 6.
37. See id. at 5 (Table 2).
38. Patricia M. Danzon, Making Sense of Drug Prices: How to Make Drugs More Af-
fordable without Stifling Beneficial Innovation and Competition, 23 REG. 56, 59
(Spring 2000), available at http://www.cato.org/pubs/regulation/regv23n1/danzon.
pdf.
39. Id. at 60.
40. Id.
41. Id. at 59-60.
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the prices of drugs sold at retail price in pharmacies and the prices of
drugs sold to HMOs and Medicaid. 42 The report concluded that the aver-
age difference between the two prices was 106 percent 43 and that the drug
manufacturers engaged in "price discrimination." '44
Some experts in the field justify differential pricing as an efficient mean
of recovering the fixed costs of R&D.45 They also explain that the al-
leged "price discrimination" stems from an economic theory known as
"Ramsey pricing," where the price-sensitive customers (in this case PBMs
and the federal government) are charged lower prices in comparison to
price-insensitive buyers (cash-paying, uninsured prescription drug con-
sumers). The experts claim that consumers as a whole are better off with
"Ramsey pricing" than with uniform pricing.46
F. RECOUPING PROFITS LOST TO FOREIGN PRICE REGULATIONS
Critics of the U.S. pharmaceutical industry allege that American con-
sumers subsidize the rest of the world's prescription drugs. They blame
the high prescription drug prices in the United States on price discrimina-
tion (to recover the cost of R&D, pharmaceutical companies charge citi-
zens of prosperous nations more, while heavily discounting drugs for
consumers in poorer countries). 47 Once manufacturers negotiate lower
prices with countries that have imposed price regulations, they raise retail
prices for consumers in the United States to make up the difference. 48
Proponents of the U.S. pharmaceutical industry deny that they engage
in cost shifting to maximize revenues. They assert that cost shifting is
simply inconsistent with profit-maximization goals of pharmaceutical
firms.4
9
III. WHY ARE DRUGS SO MUCH CHEAPER IN CANADA?
The General Accounting Office (GAO) reported in 1992 that prescrip-
tion drugs in Canada cost much less than they do in the United States.50
As stated in section I, prices of common drugs such as Prozac and Tamox-
ifen exemplify the cost differences between the two countries. One rea-
son for Canada's lower drug prices is its government-imposed price
42. Id. at 60. See generally, Minority Staff Special Investigations Div. COMM. ON
GOV'T. REFORM U.S. HOUSE OF REPRESENTATIVES, 106th CONG., Prescription
Drug Pricing in the United States: Drug Companies Profit at the Expense of Older
Americans (Nov. 9, 1999), available at http://www.house.gov/reform/min/pdfs/pdf-
inves/pdfprescrip-pricing-us rep.pdf [hereinafter MINORITY STAFF REPORT].
43. Danzon, supra note 38, at 59.
44. MINORITY STAFF REPORT, supra note 42, at 3.
45. For a discussion how the efficiency is achieved see Danzon, supra note 38, at 61.
46. See Danzon, supra note 38, at 61.
47. Lenzner, supra note 8, at 3.
48. See Pharmacuetical Companies, supra note 28.
49. Danzon, supra note 38, at 62.
50. See Michael B. Moore, "Open Wide" (Your Pocketbook That Is!) - A Call for the
Establishment in the United States of A Prescription Drug Price Regulatory Agency,
1 Sw. J. L. & TRADE AM. 149, 150 (1994).
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regulatory scheme, controlling the price pharmaceutical manufacturers
may charge. 51 In the 1960s, drugs in Canada were among the highest
priced in the world. The government saw that this was the result of its
patent protection scheme. 52 Canada passed an act requiring compulsory
licensing of drug patents. 53 Compulsory licensing allows generic drug
manufacturers to enter the market before the patent expires for a brand-
name drug.54 If the manufacturer did not accept the price set by the gov-
ernment, the government would force the drug-maker to license the
product to a manufacturer who would produce a generic.55 Some experts
believe that the practice drives down prices so that manufacturers cannot
recoup their R&D expenses.5 6
As a result, in 1987 Parliament passed Bill C-22, which gave the Cana-
dian patent-holder an exclusive right to market the drug for the first
seven years of the patent term. 57 Then in anticipation of NAFTA, in
1993, Canada enacted Bill C-91 to eliminate compulsory licensing and
extend patent protections in pharmaceuticals from seven to twenty
years.5 8 Bill C-91 contained a sunset provision, and in 1997 Parliament
voted to retain the legislation. 59
Bill C-22 established the Patented Medicine Prices Review Board
(PMPRB) to enforce price controls on patented medicines. 60 PMPRB is
an independent, quasi-judicial body that has the authority to investigate
and regulate excessive pricing of patented pharmaceutical products in Ca-
nada. 6' In setting and limiting prices, the PMPRB considers the drug's
Canadian price, the price in other markets, the price of similar medicines
within Canada, Canada's Consumer Price Index, and the cost of making
and marketing the drug.62 If the PMPRB determines that the price of a
drug is too high, it can induce the manufacturer to voluntarily reduce the
price; hold a public hearing and either order the maker to reduce the
price or take away its market exclusivity; or require the patent owner to
reduce the price of another drug or remit money to the government. 63
Another reason for lower-priced drugs in Canada is that Americans
continue to be better off than Canadians financially. 64 Canadians have
51. Danzon, supra note 38, at 58.
52. Patricia I. Carter, Federal Regulation of Pharmaceuticals in the United States and
Canada, 21 Loy. L.A. INT'L & COMP. L. REV. 215, 241 (1999).
53. Danzon, supra note 38, at 58.
54. Carter, supra note 52, at 241.
55. Danzon, supra note 38, at 58.
56. Carter, supra note 52, at 242.
57. Id.
58. Id. at 243.
59. Id. at 244.
60. Id. at 245.
61. John R. Graham, Why tme Difference between Canadian & American Prices for
Prescription Drugs is Widening, FRASER FORUM 32 (Sept. 2002).
62. See Patented Medicines Prices Review Board: Background Paper on the Price Re-
view Process for New Patented Drug Products 1 (June 1999), available at http://
www.pmbrb-cepmb.gc.ca/pdf/wg/wg2002-a4e.pdf [hereinafter PMPRB].
63. Carter, supra note 52, at 246.
64. See Graham, supra note 61.
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become poorer than Americans in recent years. In 1987, Gross Domestic
Product (GDP) per capita in the United States was 20 percent greater
than Canada, but this gap widened to 55 percent in 2001.65 Accordingly,
not just prescription drugs, but almost all goods and services, such as au-
tomobiles and computer software, cost less in Canada because Canadi-
ans' incomes are decreasing relative to those of Americans. 66
In addition to governmental price regulations in Canada and the higher
standard of living in the United States, there is another factor responsible
for the price difference between the two countries. The United States is a
more litigious country than Canada and the higher prices in the United
States reflect the increased costs of legal liability. Many federal and state
regulatory mandates for the healthcare industry impose greater risk of
product liability litigation on pharmaceutical manufacturers in the United
States; 67 hence the higher liability risks in the United States account for
part of the price difference of pharmaceuticals in the two countries.
IV. OPTIONS FOR AMERICANS SEEKING
CHEAPER MEDICINE
Until Congress implements measures to lower the burden on senior
citizens and the uninsured, some Americans have come up with creative
solutions to purchase their needed prescriptions while avoiding paying
high domestic prices.
A. PURCHASING FROM INTERNET PHARMACIES
Many Americans have turned to purchasing prescriptions from online
pharmacies. In 2000, there were between 300 and 400 Internet pharma-
cies, half of which were located outside the United States.68 The Food
and Drug Administration (FDA) estimates that about two million parcels
containing regulated products enter the United States each year through
the mail. 69 During a five-week pilot project with the FDA in 2000, cus-
toms officials in Carson City, California, received 16,500 suspect packages
but were able to inspect fewer than 2,000 and seized only 720 of the sus-
pect packages examined. 70 In 1999 alone, seizure of parcels containing
controlled substances increased 450 percent, mainly due to an increase in
online pharmacies. 71
65. Id. at 32.
66. Id.
67. Id. at 33.
68. Examining Prescription Drug Re-importation: A Review of a Proposal to Allow
Third Parties to Re-import Prescription Drugs, available at http://www.energycom-
merce.house.gov/107/hearings/07252002Hearing677/Hubbardl l47print.htm [here-
inafter Hubbard] (testimony of Mr. William Hubbard, Senior Associate
Commissioner for Policy, Planning and Legislation, FDA at the hearing before the






Internet pharmacies offer many conveniences. The consumer can ac-
cess drug prices, comparison shop, and purchase from the cheaper pro-
vider.72 Online pharmacies eliminate the need to travel to a traditional
pharmacy so the disabled and those living far away from a pharmacy have
better access to prescriptions.73 In addition, purchasing prescriptions on-
line offers some anonymity; customers may talk with a pharmacist over
the phone or via e-mail and not be concerned about bystanders
overhearing.7 4
Buying from online pharmacies has negative consequences as well.
Since some Internet pharmacies provide drugs to patients without a pre-
scription, consumers can self-medicate rather than receive proper direc-
tion from a licensed physician. 75 Many rogue pharmacies are currently
operating online businesses, and consumers may be susceptible to getting
out-of-date medicines or mislabeled dosage instructions. 76 The Attorney
Generals of several states have filed suits against rogue pharmacies oper-
ating without licenses. Some of these suits have met success in Ohio, Mis-
souri, Texas, and Kansas. 77
To ensure patient safety, the National Association of Boards of Phar-
macy (NABP) established a program called Verified Internet Pharmacy
Practice Sites (VIPPS).78 This program is designed to assist the public in
identifying properly licensed Internet pharmacies that have agreed to
comply with federal and state laws. It is a voluntary program to which
the online pharmacies may apply.7 9 Consumers may want to choose
pharmacies from the VIPPS list in order to benefit from the consumer
protection plan. Online shoppers should price carefully, as well, because
shipping charges might make the total price cost more than purchasing
from a traditional pharmacy.
B. TRAVELING TO CANADA TO PURCHASE PRESCRIPTION DRUGS
Many U.S. consumers have turned to our northern neighbor to fulfill
their prescription drug needs: Canadian pharmacies.8 11 The data for 1998
indicated brand-name drug prices in the United States were 60 percent
72. Kerry Toth Rost, Policing the "Wild West" World of Internet Pharmacies, 55 FooD
DRUG L.J. 619, 622 (2000).
73. Id.
74. Id.
75. Id. at 623.
76. Id.
77. See id. at 632-33. Ohio Attorney General has filed cease-and-desist orders against
several internet pharmacy cites; Missouri Attorney General has secured perma-
nent injunction against an online clinic and a Texas-based internet pharmacy for
providing prescription drugs without a license and only on the basis of information
provided in online consultations; Kansas Attorney General has filed restraining
orders against seven internet companies that were illegally selling prescription-
only drugs over the internet.
78. Rost, supra note 72, at 629.
79. Id.
80. See Koren, supra note 2.
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higher than Canada. 81 The price difference between the two countries
provides price-sensitive American citizens living close to the border, an
advantageous venue for obtaining their prescription needs. Although
many Americans, especially senior citizens, travel to Canada to fill their
prescriptions, this is not a viable option for poorer Americans who do not
have the resources to travel across the border to take advantage of the
money saving opportunities.
Although purchasing prescription drugs from Canada and Mexico has
been on the rise, 82 under the Federal Food and Drug Cosmetic Act
(FDCA), interstate shipment of any prescription drug that lacks required
FDA approval is illegal.83 Accordingly, importing drugs manufactured in
a foreign country into the United States is against the law.84 The FDCA,
however, permits re-importation of prescription drugs made in the
United States and exported to a foreign country only if the drug's original
manufacturer imports the drug back into the United States. 85 Although
the FDA warns Americans about the dangers of purchasing medications
from foreign countries and consistently advises against the illegal prac-
tice, the FDA has issued an informal policy guide recognizing circum-
stances when FDA field agents can choose to take no action against the
importation. 86 According to FDA's regulatory procedure manual, FDA
inspectors may exercise enforcement discretion in allowing the importa-
tion only if the intended use of the drug is for a serious condition that
does not have effective treatment domestically; the imported product
does not pose unreasonable risk; it is for personal use and does not ex-
ceed a ninety day supply; it is not promoted to U.S. residents by those
involved in the distribution of the product; the receiving individual af-
firms in writing that it is for her own use; and the individual provides a
name and address of a U.S. doctor responsible for the patient's treatment
with the product.8 7
Insurance companies have jumped on the bandwagon by providing
coverage of beneficiaries' drug purchases abroad. For example,
UnitedHealth Group has waived its requirement that the drugs would be
covered under the plan only if purchased in the United States. 88 In July
81. Graham, supra note 61, at 32.
82. Dennis Cauchon, Americans Pay More for Medicine, USA TODAY (Nov. 10, 1999),
available at http://www.usatoday.com/life/health/drugs/lhdru066.htm.
83. Id.
84. Office of Regulatory Affairs, Importation of Prescription Medicines/Drugs: Trav-
eler Alert, at http://www.fda.gov/ora/import/traveler-alert.htm (last visited Nov. 1,
2002).
85. Michelle Meadows, Imported Drugs Raise Safety Concerns, FDA CONSUMER
MAO. (Sept.-Oct. 2002), available at http://www.fda.gov/fdacfeatures/20O2/502.im-
port.html.
86. FDA Regulatory Procedure Manual, Ch. 9, Subchapter Coverage of Personal Im-
portations, available at http://www.fda.gov/ora/compliance-reflrpm-news2/ch9pers.
htm] (last visited Nov. 3, 2002).
87. See Hubbard, supra note 68.
88. Sarah Lueck, Upstart Texas Firm Makes Stir with Cheap Drugs from Canada,
WALL ST. J. (Oct. 21, 2002), available at http://www.msnbc.com (in Sept. 2002,
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2002, SPC, Inc., a Texas company that processes insurance claims and
designs health plans for unions, hospices, and managed-care companies,
created a Canadian drug program.8 9 Under this program, SPC, Inc. sends
a list of 250 drugs that are cheaper in Canada to its member consumers.
The patients obtain a prescription from their U.S. doctors, and order the
drug through Expedite-Rx. 9 1 Orders are then placed with Cross Border
Pharmacy in Calgary, which then forwards orders to Canadian doctors.
The doctors re-write the prescriptions, send them back to Cross Border
Pharmacy who fills them and mail the drugs to the patients. 9' Since so
many Americans, especially senior citizens, are resorting to obtaining
drugs from Canada, insurance companies have decided not to penalize
them for buying cheaper drugs, but rather to offer coverage of the drugs.
V. CURRENT LEGISLATION ADDRESSING
HIGH DRUG PRICES
Congress has been receptive to the American public's concern for the
consistent rise in the cost of prescription drugs. As a result, various popu-
lar solutions have emerged; some have avid supporters, and others have
been criticized severely. Congress is attempting to pass legislation that
would curb the rising price of prescription drugs in the United States.
A. LEGISLATION TO EASE ENTRY OF GENERIC DRUGS
INTO THE MARKET
By an overwhelming majority vote of 78-21, on July 31, 2002, the Sen-
ate passed S.812, Greater Access to Affordable Pharmaceutical Act
(GAAP), sponsored by Senators Charles Schumer of New York and John
McCain of Arizona. 92 During the past two years, about 45 percent of all
prescriptions filled in the United States were generic drugs. 93 Generic
UnitedHealth Group told 97,000 of its insurers that it would cover the costs of




92. See Markian Hawryluck, Bill would ease Access to Generic Drugs, AMEDNEWS.
COM (Aug. 19, 2002), available at http://www.ama-assn.org/sci-pubs/amnews/pick
02/gvsbO8l9.htm; see also Examining Issues Related to Competition in the Pharma-
ceutical Marketplace: A Review of the FTC Report, 'Generic Drug Entry Prior to
Patent Expiration,' available at http://www.energycommerce.house.gov/107/hear-
ings/10092002Hearing745/Crawford1221print.htm [hereinafter Generic Drug En-
try] (statement of The Honorable Lester Crawford D.V.M., Ph.D, Deputy
Commissioner of FDA at the hearing before the Subcommittee on Health of the
House Committee on Energy and Commerce, 107th Cong. (Oct. 9, 2002)). For a
detail view of the bill, see GREATER ACCESS TO AFFORDABLE PHARMACEUTICALS
ACT OF 2002, S. 812, 107th Cong. (2002).
93. Examining Issues Related to Competition in the Pharmaceutical Marketplace: A Re-
view of the FTC Report, 'Generic Drug Entry Prior to Patent Expiration,' available
at http://energycommerce.houst.gov/107/hearings/10092002hearing745/Jaegerl223
print.htm [hereinafter Jaeger] (statement of Kathleen Jaeger, President and CEO
of the Generic Pharmaceutical Association, at the hearing before the Subcommit-
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drugs cost, on average, ten times less than their brand-name equivalent,94
and patients, on average, save about 76 percent when a generic drug is
substituted for a brand-name product.95 Out of the 10,375 drugs listed in
the FDA's Orange Book, 7,602 are available in generic form, and within
the next three years, twenty-seven brand name drugs are scheduled to go
off patent, 96 hence increasing the availability of cheaper generic drugs for
the American consumers. Having passed the Senate, the bill was before
the House of Representative's Committee on Energy and Commerce,
and on October 9, 2002, the Subcommittee on Health held hearings to
examine the issues surrounding the need for passing the measure. 97
The 1984 Hatch/Waxman Act 98 was enacted to achieve the dual objec-
tives of guaranteeing a period of market exclusivity for the brand-drug
manufacturers to recoup their investments in R&D, as well as to promote
competition in the drug industry.99 But, the Federal Trade Commission
(FTC) has recently reported that drug companies are "filing frivolous
lawsuits and invoking the act to fend off competition and keep generic
drugs out of the marketplace."100 Brand-name drug manufacturers take
advantage of the protections the Hatch/Waxman Act affords them by su-
ing generic drug manufacturers each time they attempt to introduce
cheaper versions of a drug to the market. The incentive for filing a law-
suit is that the brand-name company is automatically granted a thirty-
month stay, which means the FDA is barred from approving the generic
competitor's product. t' Brand-name drug manufacturers thus benefit fi-
nancially from the additional thirty months of market exclusivity. 10 2 The
abuse is indicated by the increased rate of patent challenges in recent
years as more drug patents expired: 2 percent of all generic applications
tee on Health of the House Committee on Energy and Commerce, 107th Cong.
(Oct. 9, 2002)).
94. Id. § I 4.
95. Id. § 11 5.
96. Id. § 1 7.
97. W.J. Tauzin, Statement on Generic Drug Competition, House Committee on En-
ergy and Commerce (Oct. 9, 2002), available at http://energycommerce.house.gov/
107/news/10092002_748print.htm.
98. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C.S.
§ 5050) (repealed); see also Markian Hawryluk, Drugs without Borders: When Pre-
scription Drugs Go Over the Line, AMEDNEWS.COM (Oct. 22, 2001), available at
http://www.ama-assn.org/sci-pubs/amnews/pick-0l/gvsa1O22.htm. (Under the
Hatch/Waxman Act, brand-name drug makers are required to list the patents that
apply to each drug. Rather than requiring a generic drug maker to repeat the
extensive patent application process, the act allows the company to incorporate the
original manufacturer's safety and efficacy data by showing the generic drug is
equivalent to the brand-name product. Generics must certify equivalency for
every patent listed for a drug, or assert that a patent is invalid or not infringed. If
the original manufacturer sues to challenge those assertions, it triggers a thirty
month protection against the generic competitor.)
99. Jaeger, supra note 93.
100. Bush proposes rules to boost generic drugs, CNN.C!oM. (Oct. 22, 2002), available at
http://www.cnn.com/2002/ALLPOLITICS/10/21/bush.generic.drugs.index.html.
101. Jaeger, supra note 93.
102. Id. For a detailed description, refer to section B: The Current System is Being
Abused to the Detriment of American Consumers.
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were challenged in 1984-1989, whereas 28 percent were challenged in
2001.0 3 The dramatic increase demonstrates the need for an immediate
response by Congress to relieve the generic drug manufacturers from the
brand-name drug makers invoking the Hatch/Waxman Act to delay the
introduction of generic drugs into the market. 104
One of the main objectives of GAAP is to ease the introduction of
generic drugs into the market upon the expiration of the brand-name
manufacturer's patent by closing loopholes that the brand-name manu-
facturers are currently using to extend their patent protections. 0 5
Twenty-seven "blockbuster" drugs are scheduled to lose their patent pro-
tection in the next five years.10 6 Advocates of GAAP urge Congress to
pass the bill to prevent further attempts to delay production of generic
drugs.107
The main provisions of GAAP include: 1) limiting brand-name manu-
facturers to a single thirty-month stay upon filing suit against generic
manufacturers; 2) banning collusion between a generic and brand-name
manufacturers to prevent a generic alternative from coming to the mar-
ket; 3) providing a means for competitors to challenge the relevancy of
patents listed by brand-name manufacturers; and 4) allowing re-importa-
tion of U.S.-made drugs from Canada with the Health and Human Ser-
vices Secretary's approval. 10 8 Congressional Budget Office reports that
Americans will save $60 billion dollars in the next ten years if Congress
enacts GAAP into law.' 0 9 The passage of GAAP could be an important
move toward providing Americans with lower-price prescription drugs.
B. LEGISLATION TO LEGALIZE RE-IMPORTATION
During the long Senate debates over S.812 (GAAP), Senator Byron
Dorgan of North Dakota succeeded in adding an amendment to S.812
that would allow re-importation of prescription drugs by pharmacists and
wholesalers for resale. 1 10 S.812 would allow for more drugs to be re-im-
ported than is currently permitted under the Food Drug and Cosmetic
Act, which allows only manufacturers to re-import. 1t ' An increase in re-
103. Id.
104. Jaeger, supra note 93. The FTC has concluded in its report that indeed there were
no instances that the generic drug entering the market was later found to be in-
fringing on the brand's patent.
105. Hawryluk, supra note 98.
106. Jaeger, supra note 93.
107. Id. The FTC issued its final report in July 2002, finding that the thirty month stay
is being abused and delays competition.
108. Hawryluk, supra note 98.
109. Jaeger, supra note 93, at 7.
110. Markian Hawryluk, Efforts Continue for Drug Reimportation, AMEDNEWS.COM
(Aug. 12, 2002), available at http://www.ama-assn.org/sci-pubs/amnews/pick-02/
gvscO8l2.htm.
111. Hubbard, supra note 68.
2003]
440 LAW AND BUSINESS REVIEW OF THE AMERICAS [Vol. 9
imported drugs should result in higher savings to American consumers. t12
The amendment was passed, along with GAAP, when the Senate voted in
July 2002.
This is not the first time that Congress has enacted such a measure. In
October 2000, during the Clinton administration, Congress enacted the
Medicine Equity and Drug Safety Act (MEDSA), a measure similar to
GAAP."13 A provision of MEDSA requires the Secretary of Health and
Human Services (HHS) to certify, before the Act becomes effective, that
implementation of the measure will achieve the goals of providing signifi-
cant cost savings to Americans and ensuring the public's health and
safety.1 14
Both the Clinton and Bush administrations have declined to implement
MEDSA.11 5 In December 2000, HHS Secretary, Donna Shalala, stated
that the legislation had too many weaknesses to be implemented. 1a6 In
July 2001, the Bush administration also refused to implement the measure
due to safety concerns.' 17 The current re-importation legislation, GAAP,
recently passed by the Senate, contains a verification provision similar to
MEDSA. Senator Thad Cochran of Mississippi succeeded in adding an
amendment to GAAP requiring the Secretary of Health and Human Ser-
vices to certify before the law is implemented that re-importation is safe
and cost effective. 118
The Bush Administration is concerned that GAAP, in its current form,
will compromise consumer safety. 1 9 Another critic of the legislation is
the current HHS Secretary, Tommy Thompson, who believes that the
drug re-importation proposals introduced this year and in previous years
"would create unacceptable risks of adulterated, outdated, mislabeled, or
otherwise unsafe medications.' 20 Drafters of GAAP changed several
provisions in MEDSA to adjust for the concerns that Secretary Shalala
expressed as central to her refusal to implement MEDSA.
Although MEDSA and GAAP are similar conceptually, they differ in
two key aspects. MEDSA of 2000 allows "covered products" (prescrip-
112. Nat'l. Ass'n of Health Underwriters Washington Update, Medicare Reform (Aug.
2, 2002), available at http://www.nahu.org/goernment/newsletters/washington/
washUpdate_08-01-02.htm [hereinafter Medicare Reform].
113. Hawryluk, supra note 98.
114. See Medicine Equity and Drug Safety Act, 21 U.S.C.S. § 384 (1) (2002).
115. Hawryluk, supra note 98.
116. Examining Prescription Drug Reimportation: A Review of a Proposal to Allow
Third Parties to Reimport Prescription Drugs. available at http://energycommerce.
house.gov/107/hearings/07252002Hearing677/Hutt 1150print.htm (testimony of Mr.
Peter Barton Hutt, partner in the law firm of Covington & Burling, at the hearing
before the Subcommittee on Health of the House Committee on Energy and Com-
merce, 107th Cong. (July 25, 2002).
117. Hawryluk, supra note 110.
118. Medicare Reform, supra note 112.
119. Office of Management and Budget, The Executive Office of the President, State-
ment of Administration Policy on S. 812 - Greater Access to Affordable Pharma-
ceuticals, (July 18, 2002), available at http://www.whitehouse.gov/omb/legislative/
sap/107-2/S812-s.html.
120. Hawryluk, supra note 110.
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tion drugs that are not controlled substances) to be imported from Aus-
tralia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa,
and the European Union by wholesalers and pharmacies. 121 GAAP on
the other hand, in its current form, permits re-importation of drugs into
the United States from Canada only.122
GAAP also contains a clause that addresses personal importation of
medicine from Canada. 123 GAAP would permit individuals to import
prescription drugs for personal use, but not more than a ninety-day sup-
ply purchased from a licensed Canadian pharmacy registered with the
Secretary of HHS and accompanied with a copy of a valid prescription. 124
MEDSA of 2000 does not contain a provision addressing personal
importation.
Opponents of GAAP are concerned that patients will be at risk if such
measures are implemented. 25 They believe that "no other country has as
strong a regulatory structure protecting its pharmaceutical products as
the United States.' 26 The FDA resists implementing any measure that
would legalize re-importation of prescription drugs because of fear of
harm to Americans from drugs imported from other countries that do not
subject drug companies to the "gold standard" used in the United
States.' 27 The Administration is concerned also with the broad provi-
sions of the personal importation measures because their effect is to over-
ride the existing statutes that allow the FDA to refuse entry of prescrip-
tion drugs from Canada if they are believed to be unsafe, adulterated, or
counterfeit. 28
Alan Sager, Ph.D., professor of health services at the Boston Univer-
sity School of Public Health, believes that the pharmaceutical industry's
reaction would retard the impact of any re-importation measures. 129 For
one, it is unrealistic to think that the United States could purchase the
necessary quantity of drugs from Canada, because the drug companies
would be unwilling to first "ship to Canada the volume of drugs needed
to support the much bigger U.S. market."' 30
Supporters of the re-importation legislation believe that because so
many people are already crossing the border to get prescription drugs, it
makes sense to formally legalize the practice.13' It remains to be seen
how the House of Representative will vote on the bill.
121. 21 U.S.C.S. § 384(f).
122. GREATER ACCESS TO AFFORDABLE PHARMACEUTICALS ACT OF 2002, S. 812,
107th Cong. § 804(b) (2002).
123. S. 812 § 804 (k)(3).
124. See id.
125. Hawryluk, supra note 110.
126. Id.
127. See generally, Hubbard supra note 68.
128. Id.




442 LAW AND BUSINESS REVIEW OF THE AMERICAS [Vol. 9
VI. CONCLUSION
With the advance of science in biomedicine and the discovery of inno-
vative new medicines, comes a constant rise in prescription drug prices.
Many uninsured Americans do not have access to life-saving, innovative
drugs due to high prices. Although senior citizens and the uninsured
have found alternatives to paying high retail prices for prescription drugs
in the United States, most of these alternatives expose them to health or
legal risks.
Legislators have begun to experiment with new ideas for resolving the
problem of the high prescription drug prices in the United States, but it
will be some time before a consensus is reached. In the meanwhile, some
individuals who have the means will continue to purchase their medicines
from our neighboring countries; and those who cannot, will suffer. Per-
haps the United States could learn a lesson from its northern neighbor
and other countries in how to successfully control drug prices and make
prescription drugs accessible to its citizens. A further study of other
health care systems may be a way to assist the United States in devising a
prescription drug plan that better balances the demands of a free market,
capitalism, equal access, and those in need of medication.
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